Primary myelofibrosis: genes and variants
Explore variant evidence for Primary myelofibrosis across 7 analyzed proteins (MPL, JAK2, ACVR1, CALR, FLT3 and 2 more). Linked ClinVar records include 5 pathogenic or likely pathogenic variants, 8 variants of uncertain significance and 4 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Counts refer to the selected disease label.
Data updated 2026-10-21. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Primary myelofibrosis
MPL: Thrombopoietin receptor
Thrombopoietin signaling through this pathway drives megakaryocyte maturation, platelet production, and hematopoietic stem-cell maintenance. Activating variants can cause myeloproliferative neoplasms or hereditary thrombocytosis, whereas loss-of-function variants cause congenital amegakaryocytic thrombocytopenia.
5 ClinVar pathogenic / likely pathogenic and 3 uncertain variants in MPL have source records linked to Primary myelofibrosis. Association strength is not clinical gene validity.
JAK2: Tyrosine-protein kinase JAK2
It transmits signals from erythropoietin, thrombopoietin, growth hormone, and other cytokine receptors into STAT-dependent transcription. The V617F gain-of-function variant is a major driver of polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
0 ClinVar pathogenic / likely pathogenic and 3 uncertain variants in JAK2 have source records linked to Primary myelofibrosis. Association strength is not clinical gene validity.
ACVR1: Activin receptor type-1
It transduces BMP-family signals that regulate bone formation and developmental patterning. Recurrent activating variants cause fibrodysplasia ossificans progressiva by making connective-tissue cells abnormally responsive to osteogenic signaling, and somatic variants also occur in diffuse midline glioma.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in ACVR1 have source records linked to Primary myelofibrosis. Association strength is not clinical gene validity.
CALR: Calreticulin
It assists glycoprotein folding and buffers calcium within the endoplasmic reticulum. Somatic frameshift variants create abnormal C termini that activate thrombopoietin-receptor signaling and are major drivers of essential thrombocythemia and primary myelofibrosis.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in CALR have source records linked to Primary myelofibrosis. Association strength is not clinical gene validity.
FLT3: Receptor-type tyrosine-protein kinase FLT3
Its signaling supports survival and expansion of early hematopoietic progenitors. Internal tandem duplications and kinase-domain mutations produce constitutive activity in acute myeloid leukemia and are important prognostic markers and therapeutic targets.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in FLT3 have source records linked to Primary myelofibrosis. Association strength is not clinical gene validity.
JAK1: Tyrosine-protein kinase JAK1
It couples many cytokine receptors to STAT transcription factors and is essential for interferon, interleukin, and growth-factor signaling. Loss-of-function can cause immunodeficiency, whereas activating alterations contribute to inflammatory disease and some malignancies.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in JAK1 have source records linked to Primary myelofibrosis. Association strength is not clinical gene validity.
SH2B3: SH2B adapter protein 3
It restrains cytokine and growth-factor signaling in hematopoietic cells, including JAK-STAT pathways controlling blood-cell production. Loss-of-function variants can increase blood-cell proliferation and predispose to myeloproliferative neoplasms, while common variants influence autoimmune and hematologic traits.
0 ClinVar pathogenic / likely pathogenic and 6 uncertain variants in SH2B3 have source records linked to Primary myelofibrosis. Association strength is not clinical gene validity.
ClinVar pathogenic and likely pathogenic variants linked to Primary myelofibrosis
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| MPL P136H | 136 | Extracellular | Pathogenic / likely pathogenic (★★) |
| MPL P136R | 136 | Extracellular | Pathogenic / likely pathogenic (★★) |
| MPL W154R | 154 | Extracellular | Pathogenic / likely pathogenic (★★) |
| MPL R102P | 102 | Extracellular | Pathogenic / likely pathogenic (★★) |
| MPL P106L | 106 | Extracellular | Pathogenic / likely pathogenic (★★) |
Same protein, different disease
- Congenital amegakaryocytic thrombocytopenia also has ClinVar records linked to MPL variants; they fall mostly in different places as the Primary myelofibrosis variants (19 pathogenic / likely pathogenic).
- Essential thrombocythemia also has ClinVar records linked to MPL variants; they fall partly in the same places as the Primary myelofibrosis variants (8 pathogenic / likely pathogenic).
Diseases related to Primary myelofibrosis
- Thrombocythemia, also linked to CALR, JAK2, MPL and SH2B3
- Hypothyroidism, also linked to FLT3, JAK1 and SH2B3
- Acute myeloid leukemia, also linked to FLT3 and JAK2
- Crohn disease, also linked to JAK1 and JAK2
- Essential thrombocythemia, also linked to JAK2 and MPL
- Primary familial polycythemia due to EPO receptor mutation, also linked to JAK2 and SH2B3
- Gastrointestinal stromal tumor, also linked to FLT3
- Congenital amegakaryocytic thrombocytopenia, also linked to MPL
- Multiple myeloma, also linked to FLT3
- Progressive myositis ossificans, also linked to ACVR1
- Type 1 diabetes mellitus, also linked to SH2B3
- Inflammatory bowel disease, also linked to JAK2
Frequently asked questions
Which genes have records linked to Primary myelofibrosis?
This view contains 7 analyzed proteins: MPL, JAK2, ACVR1, CALR, FLT3 and 2 more. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 5 pathogenic or likely pathogenic variants, 8 variants of uncertain significance and 4 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 29 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center